TABLE 5

Associations of individual triglyceride SNPs and weighted allele score with fasting glucose and fasting insulin meta-analyzed across the four studies of nondiabetic individuals

SNPNearest gene*SNP(s) vs. fasting glucoseSNP(s) vs. fasting insulin
Fasting glucose z score per allele (95% CI)PHeterogeneity P (I2%)Expected effect size in SDs (= a × b)Fasting glucose z score per allele (95% CI)PHeterogeneity P (I2%)Expected effect size in SDs (= a × b)
rs2954029TRIB10.02 (−0.01 to 0.05)‡0.290.41 (0.0)0.01 (−0.02 to 0.05)‡0.450.22 (32.4)
rs714052MLXIPL0.00 (−0.04 to 0.05)‡0.860.43 (0.0)−0.01 (−0.06 to 0.04)‡0.590.75 (0.0)
rs7557067APOB−0.04 (−0.07 to −0.00)‡0.040.09 (53.2)−0.03 (−0.07 to 0.01)‡0.160.44 (0.0)
rs17216525NCAN, CLIP2, PBX40.01 (−0.05 to 0.06)‡0.860.55 (0.0)−0.02 (−0.08 to 0.04)‡0.520.21 (33.3)
rs10889353ANGPTL3−0.02 (−0.05 to 0.01)‡0.140.47 (0.0)0.02 (−0.02 to 0.05)‡0.290.54 (0.0)
rs7679PLTP−0.01 (−0.05 to 0.07)‡0.550.10 (52.8)0.02 (−0.03 to 0.06)‡0.450.31 (15.4)
rs7819412XKR6-AMAC1L20.02 (−0.01 to 0.05)‡0.110.73 (0.0)0.05 (0.02 to 0.08)‡0.0040.68 (0.0)
rs328LPL−0.03 (−0.08 to 0.02)‡0.180.34 (10.9)0.01 (−0.05 to 0.06)‡0.850.09 (54.4)
rs3135506APOA5−0.02 (−0.08 to 0.04)‡0.550.09 (54.1)−0.06 (−0.13 to 0.01)‡0.1140.75 (0.0)
rs662799APOA50.03 (−0.03 to 0.10)‡0.300.64 (0.0)0.03 (−0.04 to 0.10)‡0.380.38 (2.8)
Allele score0.00 (−0.01 to 0.01)§0.880.001 (80.9)0.01 (0.01–0.02)0.00 (−0.01 to 0.02)§0.720.13 (47.6)0.05 (0.04–0.05)
Q2 vs. Q1−0.02 (−0.09 to 0.04)||0.410.28 (21.9)0.03 (0.02–0.04)0.02 (−0.05 to 0.10)||0.450.54 (0.0)0.09 (0.06–0.11)
Q3 vs. Q1−0.01 (−0.08 to 0.05)||0.740.22 (31.3)0.04 (0.03–0.05)0.04 (−0.03 to 0.16)||0.270.01 (73.3)0.13 (0.12–0.14)
Q4 vs. Q1−0.04 (−0.10 to 0.03)||0.270.20 (34.6)0.05 (0.04–0.06)−0.02 (−0.10 to 0.05)||0.530.22 (31.8)0.16 (0.13–0.18)
Q5 vs. Q10.01 (−0.06 to 0.08)||0.740.004 (77.7)0.07 (0.06–0.09)0.04 (−0.03 to 0.11)||0.310.10 (52.7)0.24 (0.21–0.27)
  • Q = quintile of weighted allele score.

  • *Nearest gene information reported as in Kathiresan et al. (31), except for rs328, which is from Kathiresan et al. (34), and for rs3135506 and rs662799, which are from Pennacchio et al. (32).

  • †The point estimate of the expected effect size for the allele score vs. outcome was calculated by multiplying (Fig. 1a) the effect size of the allele score vs. triglyceride association by (Fig. 1b) the effect size of the relevant triglyceride vs. outcome association. For example, the expected effect size for the allele score vs. fasting glucose was calculated by multiplying the effect size of the allele score vs. triglyceride association (0.12 SDs) by the effect size of the triglyceride vs. fasting glucose association (0.12 SDs).

  • The effect sizes reported are ‡change in fasting glucose/fasting insulin z score per triglyceride-raising allele for individual SNPs,

  • §change in fasting glucose/fasting insulin z score per unit increase in weighted allele score, or

  • ||difference in fasting glucose/fasting insulin z score between the relevant quintiles of the weighted allele score.

  • The sample sizes for allele score vs. outcome analyses were 8,040 and 6,544 for fasting glucose and fasting insulin, respectively. For the quintiles of allele score vs. outcomes, the sample sizes ranged from 3,197 to 3,216 and from 2,633 to 2,643 for fasting glucose and fasting insulin, respectively.